A detailed history of Woodline Partners LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 481,752 shares of NTLA stock, worth $6.32 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
481,752
Holding current value
$6.32 Million
% of portfolio
0.09%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $9.5 Million - $13.2 Million
481,752 New
481,752 $9.9 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $5.01 Million - $9.47 Million
150,991 Added 43.48%
498,262 $17.4 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $15.6 Million - $20.7 Million
288,610 Added 492.0%
347,271 $19.4 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $2.26 Million - $4.47 Million
58,661 New
58,661 $3.04 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $997M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.